Top-News
RXI Pharma
Beiträge: 51
Zugriffe: 16.541 / Heute: 7
Zugriffe: 16.541 / Heute: 7
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,63%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +37,52%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +35,27%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +33,28%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +28,13%
www.prnewswire.com/news-releases/...e-iib-to-iv-300067738.html
www.boerse-frankfurt.de/de/aktien/...c+dl+0001+ag+US74979C3034
...bisher mein größter Verlust ( noch nicht realisiert) dieses Jahr.
Dann hoff ich mal auf bessere Zeiten...eigentlich bisher keine schlechten Nachrichten, aber die Aktie wird massiv geshortet...das könnte natürlich heute mit dieser Nachricht sauber in die andere Richtung drehen!
Dann hoff ich mal auf bessere Zeiten...eigentlich bisher keine schlechten Nachrichten, aber die Aktie wird massiv geshortet...das könnte natürlich heute mit dieser Nachricht sauber in die andere Richtung drehen!
MARLBOROUGH, Mass., Sept. 28, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China (SIPO) for the composition and methods of use for RXI-109 and other connective tissue growth factor (CTGF) targeting self-delivering RNAi compounds (sd-rxRNA®) for the treatment of fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031.
Logo - photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXI-109 and other CTGF-targeting sd-rxRNA® compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.
"We are pleased with the issuance of this core patent which covers RXI-109 in China," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, "Not only does this patent further strengthen our intellectual property portfolio, it also expands regional out-licensing and partnering opportunities available with our self-delivering platform. This comes at an important time as we accelerate our business development efforts, one of our seven key initiatives for increasing shareholder value."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of disorders such as alopecia areata, warts, non-malignant skin tumors and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial is planned to initiate this year in ophthalmology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
Logo - photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXI-109 and other CTGF-targeting sd-rxRNA® compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.
"We are pleased with the issuance of this core patent which covers RXI-109 in China," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, "Not only does this patent further strengthen our intellectual property portfolio, it also expands regional out-licensing and partnering opportunities available with our self-delivering platform. This comes at an important time as we accelerate our business development efforts, one of our seven key initiatives for increasing shareholder value."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of disorders such as alopecia areata, warts, non-malignant skin tumors and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial is planned to initiate this year in ophthalmology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
www.nasdaq.com/de/symbol/rxii/real-time
ih.advfn.com/stock-market/NASDAQ/...rporation-RXII/stock-price
kein kauf-oder verkaufempfehlung ( ich selbst bin nicht drin )
kein kauf-oder verkaufempfehlung ( ich selbst bin nicht drin )
rein Freitag natürlich schon im minus wie immer. hört sich aber gut an.
noch besser finde ich allerdings die Story von Phase RX kommen von 5 Dollar sind derzeit bei 1,50 Dollar Handelsvolumen 100,000 Stück davon habe ich 5,000 abgestaubt LOL Sehe hier verzehfachung bis verzwanigzfachungs Potential bei 100% Risiko... Sollte hier ein Pharma oder Biotech Gigant einsteigen bzw. die Plattform lizensieren geht es ab:
PhaseRx has developed a therapeutics platform applicable to a host of diseases. Our initial focus is on three urea cycle disorders (UCDs) as first targets as we believe we can achieve life changing impacts within a reasonable timeframe:
•PRX-OTC for Ornithine Transarbamylase Deficiency (OTCD)
•PRX-ASL for ArgininosuccinateLyase Deficiency (ASLD)
•Argininosuccinatesynthetase 1 (ASS1) deficiency
PhaseRx believes its approach helps mitigate the costs and risks associated with biotech drug development, which are often attributable to a poor understanding of the disease biology and the mechanism of action of the drug candidate, as well as the need for large clinical trials and uncertainty about approvable endpoints. We believe our costs and risks will be lower because:
•The biology of our disease programs is well understood: our target diseases are caused by a bad gene inherited from parents that results in a defective or missing enzyme inside the liver cell.
•The mechanism of action of our therapeutics is clear: we are simply replacing the missing enzyme using our intracellular enzyme replacement therapy approach.
•Clinical proof of concept can be obtained in relatively few patients: We believe we can obtain clinical proofs of concept in very few (10-20) patients, and ultimately achieve product registration based on 30-40 patients, as opposed to hundreds or even thousands of patients needed to obtain clinical proof of concept and registration in other diseases, such as cancer, diabetes, etc.
There is an approvable endpoint in lead programs: We believe lowering of blood ammonia is an approvable endpoint for our lead urea cycle disease (UCD) programs, since an ammonia scavenger was approved by FDA in 2013 for the treatment of the UCDs on the basis of lowering blood ammonia. Also, ammonia can be quickly and readily measured by a blood assay.
phaserx.com/pipeline/
noch besser finde ich allerdings die Story von Phase RX kommen von 5 Dollar sind derzeit bei 1,50 Dollar Handelsvolumen 100,000 Stück davon habe ich 5,000 abgestaubt LOL Sehe hier verzehfachung bis verzwanigzfachungs Potential bei 100% Risiko... Sollte hier ein Pharma oder Biotech Gigant einsteigen bzw. die Plattform lizensieren geht es ab:
PhaseRx has developed a therapeutics platform applicable to a host of diseases. Our initial focus is on three urea cycle disorders (UCDs) as first targets as we believe we can achieve life changing impacts within a reasonable timeframe:
•PRX-OTC for Ornithine Transarbamylase Deficiency (OTCD)
•PRX-ASL for ArgininosuccinateLyase Deficiency (ASLD)
•Argininosuccinatesynthetase 1 (ASS1) deficiency
PhaseRx believes its approach helps mitigate the costs and risks associated with biotech drug development, which are often attributable to a poor understanding of the disease biology and the mechanism of action of the drug candidate, as well as the need for large clinical trials and uncertainty about approvable endpoints. We believe our costs and risks will be lower because:
•The biology of our disease programs is well understood: our target diseases are caused by a bad gene inherited from parents that results in a defective or missing enzyme inside the liver cell.
•The mechanism of action of our therapeutics is clear: we are simply replacing the missing enzyme using our intracellular enzyme replacement therapy approach.
•Clinical proof of concept can be obtained in relatively few patients: We believe we can obtain clinical proofs of concept in very few (10-20) patients, and ultimately achieve product registration based on 30-40 patients, as opposed to hundreds or even thousands of patients needed to obtain clinical proof of concept and registration in other diseases, such as cancer, diabetes, etc.
There is an approvable endpoint in lead programs: We believe lowering of blood ammonia is an approvable endpoint for our lead urea cycle disease (UCD) programs, since an ammonia scavenger was approved by FDA in 2013 for the treatment of the UCDs on the basis of lowering blood ammonia. Also, ammonia can be quickly and readily measured by a blood assay.
phaserx.com/pipeline/
Bin durch Opko Heath die ich auch gekauft habe auf diesen Wert aufmerksam geworden. Stellen Diagnostic Geräte her + Schwesterfirma mit Medikamentenerforschung Biotech + Beteiligungen an kleinen Start-UP Biotechs:
RXi Pharmaceuticals Corp (NASDAQ:RXII) investors should be smiling today, after drug maker Opko Health (NASDAQ:OPK) disclosed in a SEC filing a 5.11% passive stake (446,360 shares) in RXII.
Reacting to the disclosure, RXi Pharmaceuticals shares are rising nearly 25% to $0.88 in early trading Friday.
RXi Pharmaceuticals Corp (NASDAQ:RXII) investors should be smiling today, after drug maker Opko Health (NASDAQ:OPK) disclosed in a SEC filing a 5.11% passive stake (446,360 shares) in RXII.
Reacting to the disclosure, RXi Pharmaceuticals shares are rising nearly 25% to $0.88 in early trading Friday.
1 für 10 Re-Split um die 1,-$-Regel der Nasdaq zu erfüllen.
Vollzug schon am 08.01.2018
"MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018"
http://www.ariva.de/news/...als-announces-reverse-stock-split-6714477
Kurs gestern nur noch 0,4688$
Am Montag dann bei ca. 4,68$
Vollzug schon am 08.01.2018
"MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018"
http://www.ariva.de/news/...als-announces-reverse-stock-split-6714477
Kurs gestern nur noch 0,4688$
Am Montag dann bei ca. 4,68$
Kommt mal wieder etwas Leben rein..
http://www.ariva.de/rxi_pharmaceuticals-aktie/...refsInput=&xyz=1
http://www.ariva.de/rxi_pharmaceuticals-aktie/...refsInput=&xyz=1
hilft hier wohl zusätzlich zum engen Markt.
Geht ja voll ab... Damit die Marktkapi schon bei 10Mio... ;)
schau mal auf den Freitagsclose in Stuttgart vs. Frankfurt.... Vielleicht eine abenteuerliche Geldtaxe? Bezogen auf Frankfurt ist da kein Sprung
|
Neueste Beiträge aus dem Phio Pharmaceuticals Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 518 | Phio Pharmaceuticals | DA_BUA | RichyBerlin | 06.03.24 22:47 | |
| 50 | RXI Pharma | iwanooze | iTechDachs | 25.04.21 01:19 |
